Oral Oncology
Volume 38, Issue 8 , Pages 752-756 , December 2002

Bcl-xL antisense treatment sensitizes Bcl-xL-overexpressing squamous cell carcinoma cells to carboplatin

  • M Itoh

      Affiliations

    • Department of Immunology, Tokyo Medical University, 6-1-1 Shinjuku, Shinjuku-ku, Tokyo 160-0022, Japan
    • ,
  • T Noutomi

      Affiliations

    • Department of Oral and Maxillofacial-Surgery, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama 359-8513, Japan
    • ,
  • H Chiba

      Affiliations

    • Department of Oral and Maxillofacial-Surgery, Tokyo Medical University Hospital, 6-7-1 Nishi-Shinjuku, Shinjuku-ku, Tokyo 160-0023, Japan
    • ,
  • J Mizuguchi

      Affiliations

    • Department of Immunology, Tokyo Medical University, 6-1-1 Shinjuku, Shinjuku-ku, Tokyo 160-0022, Japan
    • Intractable Disease Research Center, Tokyo Medical University, 6-1-1 Shinjuku, Shinjuku-ku, Tokyo 160-0022, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81-3-3351-6141; fax: +81-3-3341-2941

Received 30 May 2002 ,Accepted 19 June 2002.

References 

  1. Zamboglou N, Schnabel T, Kolotas C, Achterrath W, Strehl H, Dalhauser S, et al.  Carboplatin and radiotherapy in the treatment of head and neck cancer: six years' experience. Seminars in Oncology. 1994;21:45–53
  2. Niitani H, Kobayashi K. Cisplatin/carboplatin therapy in non-small cell lung cancer. Oncology. 1992;49(Suppl 1):51–56
  3. Brockstein BE, Vokes EE. Oral chemotherapy in head and neck cancer. Drugs. 1999;58(Suppl 3):91–97
  4. Eastman A. Mechanisms of resistance to cisplatin. Cancer Treatment and Research. 1991;57:233–249
  5. Costantini P, Jacotot E, Decaudin D, Kroemer G. Mitochondrion as a novel target of anticancer chemotherapy. Journal of The National Cancer Institute. 2000;92:1042–1053
  6. Antonsson B, Martinou JC. The Bcl-2 protein family. Experimental Cell Research. 2000;256:50–57
  7. Gross A, McDonnell JM, Korsmeyer SJ. BCL-2 family members and the mitochondria in apoptosis. Genes and Development. 1999;13:1899–1911
  8. Reed JC, Kroemer G. Mechanisms of mitochondrial membrane permeabilization. Cell Death and Differentiation. 2000;7:1145
  9. Itoh M, Chiba H, Noutomi T, Takada E, Mizuguchi J. Cleavage of Bax-alpha and Bcl-x(L) during carboplatin-mediated apoptosis in squamous cell carcinoma cell line. Oral Oncology. 2000;36:277–285
  10. Reed JC. Bcl-2 family proteins. Oncogene. 1998;17:3225–3236
  11. Marzo I, Brenner C, Zamzami N, Jurgensmeier JM, Susin SA, Vieira HL, et al.  Bax and adenine nucleotide translocator cooperate in the mitochondrial control of apoptosis. Science. 1998;281:2027–2031
  12. Shimizu S, Narita M, Tsujimoto Y. Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC. Nature. 1999;399:483–487
  13. Noutomi T, Chiba H, Itoh M, Toyota H, Mizuguchi J. Bcl-x(L) confers multi-drug resistance in several squamous cell carcinoma cell lines. Oral Oncology. 2002;38:41–48
  14. Decaudin D, Geley S, Hirsch T, Castedo M, Marchetti P, Macho A, et al.  Bcl-2 and Bcl-XL antagonize the mitochondrial dysfunction preceding nuclear apoptosis induced by chemotherapeutic agents. Cancer Research. 1997;57:62–67
  15. Simonian PL, Grillot DA, Nunez G. Bcl-2 and Bcl-XL can differentially block chemotherapy-induced cell death. Blood. 1997;90:1208–1216
  16. McNeil PL, Murphy RF, Lanni F, Taylor DL. A method for incorporating macromolecules into adherent cells. Journal of Cell Biology. 1984;98:1556–1564
  17. Partridge M, Vincent A, Matthews P, Puma J, Stein D, Summerton J. A simple method for delivering morpholino antisense oligos into the cytoplasm of cells. Antisense and Nucleic Acid Drug Development. 1996;6:169–175
  18. Summerton J, Weller D. Morpholino antisense oligomers: design, preparation, and properties. Antisense and Nucleic Acid Drug Development. 1997;17:187–195
  19. Beale PJ, Rogers P, Boxall F, Sharp SY, Kelland LR. BCL-2 family protein expression and platinum drug resistance in ovarian carcinoma. British Journal of Cancer. 2000;82:436–440
  20. Jansen B, Schlagbauer-Wadl H, Brown BD, Bryan RN, van Elsas A, Muller M, et al.  bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nature Medicine. 1998;4:232–234
  21. Simoes-Wust AP, Olie RA, Gautschi O, Leech SH, Haner R, Hall J, et al.  Bcl-xl antisense treatment induces apoptosis in breast carcinoma cells. International Journal of Cancer. 2000;87:582–590
  22. Fennell DA, Corbo MV, Dean NM, Monia BP, Cotter FE. In vivo suppression of Bcl-XL expression facilitates chemotherapy-induced leukaemia cell death in a SCID/NOD-Hu model. British Journal of Haematology. 2001;112:706–713
  23. Thierry AR, Dritschilo A. Liposomal delivery of antisense oligodeoxynucleotides. Application to the inhibition of the multidrug resistance in cancer cells. Annals of The New York Academy of Sciences. 1992;669:300–302
  24. Spiller DG, Tidd DM. Nuclear delivery of antisense oligodeoxynucleotides through reversible permeabilization of human leukemia cells with streptolysin O. Antisense Research and Development. 1995;5:13–21

PII: S1368-8375(02)00047-7

doi: 10.1016/S1368-8375(02)00047-7

Oral Oncology
Volume 38, Issue 8 , Pages 752-756 , December 2002

Article Tools

* Image Usage & Resolution